| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Post-Diagnosis Hemorrhagic Events Are Strongly Associated With Poor Survival in Patients With Essential Thrombocythemia. |
| 掲載誌名 | 正式名：EJHaem 略 称：EJHaem ISSNコード：26886146/26886146 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 6(4),pp.e70103 |
| 著者・共著者 | Yoshinori Hashimoto, Tomoki Ito, Akihiko Gotoh, Mika Nakamae, Fumihiko Kimura, Michiaki Koike, Keita Kirito, Hideho Wada, Kensuke Usuki, Takayuki Tanaka, Takehiko Mori, Satoshi Wakita, Toshiki I Saito, Akiko Kada, Akiko M Saito, Kazuya Shimoda, Yuka Sugimoto, Toshiro Kurokawa, Akihiro Tomita, Yoko Edahiro, Hitoshi Kiyoi, Koichi Akashi, Itaru Matsumura, Katsuto Takenaka, Norio Komatsu |
| 発行年月 | 2025/07 |
| 概要 | OBJECTIVES:The present study investigated the effects of thrombosis, hemorrhagic events, disease progression, and secondary malignancies on patient survival after the diagnosis of essential thrombocythemia (ET).METHODS:We analyzed data from 1152 patients enrolled in the JSH-MPN-18 study using time-dependent Cox regression and multistate Markov models to estimate transition hazards and state occupation probabilities.RESULTS:Hemorrhagic events (hazard ratio = 2.92, 95% confidence interval = 1.78-4.78, p < 0.001) was associated with a poor prognosis. In multistate model, hazards from the hemorrhagic event to death were higher among cumulative transition hazards, and the probability of remaining in the hemorrhagic state was lower than the probability of remaining in the other states of thrombosis, disease progression, and secondary malignancy in state occupancy probabilities.CONCLUSIONS:The present results demonstrated that hemorrhagic events following the diagnosis of ET are a serious risk factor and are directly related to early death. Baseline characteristics and post-diagnosis events (intermediate status) may both have a significant impact on survival, and treatment strategies that take into account the prevention of an intermediate status need to be incorporated into clinical practice.TRIAL REGISTRATION:The authors have confirmed clinical trial registration is not needed for this submission. |
| DOI | 10.1002/jha2.70103 |
| PMID | 40666293 |